Primary insider Anne Cecile Alvik, Head of QA and Board member (employee representative) of Oncoinvent ASA, has 5. March 2025 acquired 8 500 shares in Oncoinvent ASA at an average price of NOK 1,694 per share. Following this transaction, Anne Cecilie owns 13 200 shares in Oncoinvent ASA.

Oncoinvent ASA (OSE: ONCIN) a clinical stage 2 radiopharmaceutical company developing novel radiopharmaceutical therapies against cancer, announces its fourth quarter 2024 results today

Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the successful enrollment of the sixth patient into the safety lead-in cohort of its ongoing Phase 2 trial evaluating Radspherin® for the treatment of peritoneal carcinomatosis from ovarian cancer.

In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events:

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will be presenting the company and participate in the following conferences:

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 6 February 2025 regarding the final result of the subsequent offering in the Company, where a total of 5,500,000 new shares were subscribed and allocated at a subscription price of NOK 2 per share.

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 22 January 2025 regarding the launch of a subsequent offering of up to 5,500,000 new shares (“Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 2 per Offer Share (the “Subsequent Offering”), as well as the stock exchange announcement from earlier today, regarding today being the last day of the subscription period in the Subsequent Offering.

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 22 January 2025 regarding the launch of a subsequent offering of up to 5,500,000 new shares (“Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 2 per Offer Share (the “Subsequent Offering”).

Oncoinvent ASA (“Oncoinvent” or the “Company”) has today granted 3,560,000 share options under its long term share incentive scheme for employees (the “Option Program”), each with a strike price of NOK 2.4991 of these 2,210,000 share options were granted to primary insiders of the Company. For more information about the grant of share options to primary insiders, see the attached forms. Following today’s grant, a total of 4,789,808 share options have been granted under the Option Program.

Oncoinvent ASA (“Oncoinvent” or the “Company”) is pleased to announce that it has today successfully completed the bookbuilding process for a private placement of new shares and that gross proceeds of NOK 130 million is being raised by the issuance of 65,000,000 new shares (the “Offer Shares”) at a subscription price of NOK 2 per share (the “Private Placement”).